Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
04 August 2009 - 2:30PM
PR Newswire (US)
VANCOUVER, Aug. 4 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) today
announced the launch of a series of new, proprietary Quill(TM) SRS
product codes specifically designed for laparoscopic, or minimally
invasive, gynecology procedures, including hysterectomies and
myomectomies. In 2008, there were approximately 750,000
hysterectomies performed in the United States of which
approximately 130,000 were performed laparoscopically. In addition,
there were approximately 72,000 myomectomies performed in the
United States to remove uterine fibroid tumors. Management
estimates 6-8% annual growth in laparoscopically assisted
hysterectomies through 2014. Angiotech's proprietary Quill SRS
barbed suture technology offers significant advantages in
laparoscopic surgery whether performed manually by surgeons or
through robotic assistance. The primary advantage of Quill SRS for
laparoscopic procedures is the ability to close a wound using Quill
without the surgeon having to tie knots. The exercise of tying
knots can be very challenging and time consuming when surgeons are
relegated to operating in a smaller surgical field as a result of
electing to use a minimally invasive approach for the procedure. A
second advantage is to minimize or eliminate the need for a third
hand to maintain tension on the suture as typically required with a
traditional suturing technique in order to deal with tissue recoil.
A third advantage of Quill SRS is that the even distribution of
tension and its ability to maintain the tension along the length of
the suture also provides hemostatic benefits, often eliminating or
minimizing the need for standard hemostatic sutures. These and
other novel elements of Angiotech's Quill SRS for laparoscopic and
robotic-assisted surgery are expected to significantly reduce the
time and difficulty of completing a wound closure in these types of
surgical procedures, where tying sutures through small incisions
using instruments, while having limited visibility of patient
anatomy, can be one of the most difficult and tedious aspects of
such procedures for physicians. Patients may also benefit through
reduced surgical times, and therefore reduced time under
anesthesia, and health care facilities and payors may also benefit
from the potential to reduce operating room time needed, or the
total cost of material needed, to complete such surgical
procedures. Angiotech's new Quill SRS product codes for
laparoscopic gynecology procedures are available in our
polydioxanone (PDO) suture material in size -0- with 7 cm by 7 cm
and 14 cm by 14 cm lengths, and include our newly designed 36 mm
needles. The use of Quill SRS in laparoscopic gynecology surgery
was first reported by James Greenberg, MD, and Jon Einarsson, MD,
MPH, of the Centre for Women's Surgery at Brigham Women's/Faulkner
Hospitals and Harvard Medical School Boston, Massachusetts in the
Journal of Minimally Invasive Gynecology, in November of 2008. The
results of this small feasibility study looked at the application
of Quill SRS in myomectomy and total laparoscopic hysterectomy
vaginal cuff closures. This publication was then followed by up by
a podium presentation at the American Association of Gynecologic
Laparoscopists (AAGL) annual meeting in the fall of 2008 confirming
that there were no post operative issues or complications from the
use of Quill SRS in a patient series that had grown to 150 patients
reviewed to that date. "Bidirectional barbed sutures greatly
facilitate laparoscopic suturing. Further evolution and
incorporation of this suture material into clinical practice seems
inevitable," said Dr. Einarsson. "Quill SRS helps surgeons overcome
one of the largest obstacles in advanced minimally invasive surgery
- tying knots laparoscopically. With this revolutionary technology,
we should anticipate the introduction of the next generation of
safer minimally invasive procedures," said Dr. Greenberg. For more
information about Quill SRS for laparoscopic gynecology procedures,
please refer to our Quill SRS website located at
http://www.angioedupro.com/ and view our online movies
demonstrating Quill SRS in use. All Quill SRS products are also
available for purchase online by accredited surgeons at Angiotech's
e-commerce site which can be accessed at
https://ecommerce.angiotech.com/Main/Home.aspx. About the Quill(TM)
Self-Retaining System (SRS) The Quill SRS product line represents a
revolutionary technology in wound closure made possible by
bidirectional fixation within the wound. Its patented design allows
the surgeon to begin closure at the midpoint of the wound and
suture in two directions from the midpoint. Barbs within the Quill
SRS product distribute tension across the wound and eliminate the
need for knots. Forward Looking Statements
-------------------------- Statements contained in this press
release that are not based on historical fact, including without
limitation statements containing the words "believes," "may,"
"plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and "forward-looking
information" within the meaning of applicable Canadian securities
laws. All such statements are made pursuant to the "safe harbor"
provisions of applicable securities legislation. Forward-looking
statements may involve, but are not limited to, comments with
respect to our objectives and priorities for 2009 and beyond, our
strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our
operations, research, development, product and drug development.
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Many such risks, uncertainties and
other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among
others, the following: general economic and business conditions,
both nationally and in the regions in which we operate; market
demand; technological changes that could impact our existing
products or our ability to develop and commercialize future
products; competition; existing governmental regulations and
changes in, or the failure to comply with, governmental
regulations; adverse results or unexpected delays in pre-clinical
and clinical product development processes; adverse findings
related to the safety and/or efficacy of our products or products
sold by our partners; decisions, and the timing of decisions, made
by health regulatory agencies regarding approval of our technology
and products; the requirement for substantial funding to conduct
research and development and to expand manufacturing and
commercialization activities or consummate acquisitions; and any
other factors that may affect performance. In addition, our
business is subject to certain operating risks that may cause the
actual results expressed or implied by the forward-looking
statements in this press release to differ materially from our
actual results. These operating risks include: our ability to
attract and retain qualified personnel; our ability to successfully
complete pre-clinical and clinical development of our products;
changes in business strategy or development plans; our failure to
obtain patent protection for discoveries; loss of patent protection
resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or
controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce
timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to
maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance
of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued
availability of capital to finance our activities; and any other
factors referenced in our other filings with the Securities and
Exchange Commission ("SEC") and applicable Canadian regulatory
authorities. For a more thorough discussion of the risks associated
with our business, see the "Risk Factors" section in our annual
report for the year ended December 31, 2008 filed with the SEC on
Form 10-K, and our quarterly report for the three months ended
March 31, 2009 filed with the SEC on Form 10-Q. Given these
uncertainties, assumptions and risk factors, readers are cautioned
not to place undue reliance on such forward-looking statements.
Except as required by law, we disclaim any obligation to update any
such factors or to publicly announce the result of any revisions to
any of the forward-looking statements contained in this press
release to reflect future results, events or developments. About
Angiotech Pharmaceuticals Angiotech Pharmaceuticals, Inc. is a
global specialty pharmaceutical and medical device company with
over 1,500 dedicated employees. Angiotech discovers, develops and
markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. DATASOURCE: Angiotech Pharmaceuticals,
Inc. CONTACT: DeDe Sheel, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4412,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024